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Abstract: Lenalidomide belongs to a novel class of drugs called Immunomodulators which are now being used 
for the treatment of plasma cell dyscrasias with variable degrees of efficacy and toxicity. Though Second Primary 
Malignancies (SPM) have been a concern with its use, the benefits of the treatment outweigh the risks. The leuke-
mogenic risk seems to be potentiated especially when combined with alkylating agents and the SPMs documented 
are predominantly myeloblastic. To date there are no reported cases of new lymphocytic leukemias in AL amyloido-
sis, regardless of whether undergone treatment or not. We present a case of AL amylodosis who was treated with 
lenalidomide and subsequently developed acute lymphoblastic leukemia.
Keywords: Second primary malignancy, acute lymphoblastic leukemia, AL amyloidosis, lenalidomide
Introduction 
Plasma cell neoplasms are characterized by 
clonal proliferation of plasma cells in the bone 
marrow leading to the production of monoclo-
nal immunoglobulins. They are sometimes 
accompanied by tissue deposition of monoclo-
nal immunoglobulins or their components. 
Amyloidosis refers to a distinct group of tissue 
deposition disorders among which light-chain 
(AL) amyloidosis is the most common type. The 
introduction of lenalidomide and other immu-
nomodulators (IMiDs) as a treatment modality 
for amyloidosis was a significant breakthrough 
in this disease. Multiple trials are ongoing with 
IMiDs in combination with other drugs for the 
treatment of AL amyloidosis [1]. There have 
been rare cases in which plasma cell neo-
plasms treated with lenalidomide develop 
acute leukemia post lenalidomide treatment 
and these cases were predominantly myelo-
blastic. We describe a rare incidence of 
B-lymphoblastic leukemia in a patient with AL 
amylodosis who received lenalidomide and 
dexamethasone for 56 months.
Case 
A 73 year old female presented to our institu-
tion in the fall of 2007 with 3 month history of 
lower extremity edema. A routine complete 
blood count at the time of presentation showed 
hemoglobin of 11.5 g/dL, normal WBC count, 
and platelets 319,000/μL. Serum and urine 
protein electrophoresis with immunofixation 
detected lambda light chains. A kidney biopsy 
was obtained and showed multiple glomeruli 
with moderate to severe diffuse mesangial 
expansion with accumulations of acellular, 
weakly PAS positive material that shows red-
green birefringence staining with Congo red 
when examined under polarized light microsco-
py consistent with amyloid deposition (Figure 
1). Immunofluorescent studies demonstrated 
smudgy lambda light chain deposition in the 
interstitium and vessel walls. Kappa light chain 
was negative. The diagnosis of renal amyloido-
sis, AL lambda type involving glomeruli, intersti-
tium and vessels was rendered. Bone marrow 
studies demonstrated a population of lambda 
light chain restricted plasma cells by flow 
cytometry. The bone marrow aspirate smears 
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showed trilineage hematopoiesis and with a 
population of plasma cells, 5-8% of the total 
cellularity (Figure 2A). Congo red stain was pos-
itive for amyloid deposition. Cytogenetic and 
FISH (fluorescent in-situ hybridization) panel for 
multiple myeloma were within normal limits. 
These findings were compatible with lambda 
light chain amyloidosis.
Lenalidomide was started at 15 mg daily for 21 
days, followed by 7 days off, for a 28 day total 
cycle. Dexamethasone was given at a dose of 
20 mg weekly. She received aspirin for throm-
boembolic prophylaxis. At the initiation of treat-
ment, her serum lambda light chain level was 
60 mg/dL. There was initially a flare in her 
lambda light chains to 101 mg/dL then the lev-
els started to improve. The patient achieved 
partial hematologic response with more than 
50% reduction in the level of the serum mono-
clonal protein in less than 2 months and a com-
plete hematologic response with complete dis-
appearance of the monoclonal protein in the 
serum in 7 months. The patient continued to be 
on the same regimen for a total duration of 56 
months.
In November 2012, she presented with gener-
alized weakness, lightheadedness and easy 
bruising. On complete blood count the patient 
was found to have severe thrombocytopenia at 
16,000/μL. Her WBC count was normal at 
5,600 cells/μL and the hemoglobin was 12.0 
the cells), tetrasomy 8 and copy gains for 
5p/5q. There were no rearrangements for any 
studied probe set. Cytogenetic studies demon-
strated a normal karyotype: 46 XX. 
The patient began induction chemotherapy 
with daunorubicin, vincristine and prednisone 
and achieved a complete remission. Phase 2 of 
induction chemotherapy included cytoxan, 
cytarabine, 6-mercaptopurine and intrathecal 
methotrexate [2]. Consolidation chemotherapy 
with high dose methotrexate was administered 
and was complicated by an admission for infec-
tion and bleeding. A few months after the com-
pletion of consolidation chemotherapy, the 
patient unfortunately relapsed. Salvage chemo-
therapy was attempted with vincristine and 
dexamethasone. Due to complications of her 
disease and treatment, she eventually devel-
oped multi-organ failure and was put on com-
fort measures.
Discussion
It is estimated that more than 12 million cancer 
survivors are currently alive in the United 
States. Increasing survivorship has led to focus 
on the long-term outcome of malignancies and 
chemotherapy complications [3]. Lenalidomide 
which is a less toxic and more potent derivative 
of its parent drug, thalidomide, has renewed 
interest in the treatment of plasma cell dyscra-
sias due to its significant therapeutic activity. 
Figure 1. Renal Biopsy with insert demonstrating amyloid deposits 
showing birefringence on polarizing  microscopy after Congo red stain-
ing.
g/dL. Review of peripheral blood 
smear showed numerous blasts. 
Bone marrow studies demonstrat-
ed a markedly hypercellular mar-
row with sheets of medium sized 
blast (Figure 2B). Flow cytometric 
studies showed an expanded B- 
lymphoblast population with dim 
CD45+, bright CD38, dim-moder-
ate CD19, CD20, CD10, dim TdT, 
moderate CD34, variable CD33 
and moderate-bright HLA-DR expr- 
ession, all consistent with a diag-
nosis of B-lymphoblastic leukemia. 
FISH analysis showed copy gain of 
MYC and IGH in 13% of the nuclei, 
deletion of p53 gene in 76% of the 
cells, deletion of ABL gene in 79% 
of the cells and low levels of copy 
gain for BCR (6.5%) and MLL genes 
(9%), monosomy 7 (79.5% of the 
cells), deletion of 20q (79.5% of 
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Lenalidomide was examined in multiple phase 
2 studies for the treatment of AL amyloidosis in 
combination with other drugs. These trials 
demonstrated favorable hematologic and 
organ response rates, manageable toxicity and 
no reported cases of second primary malignan-
cy (SPM) [4-9]. Lenalidomide, along with other 
new targeted agents has dramatically improved 
the overall median survival of patients with 
amyloidosis to greater than 3 years [6, 9]. There 
is a growing concern about an increasing num-
ber of cases of SPMs associated with the use 
of lenalidomide in newly diagnosed and 
relapsed multiple myeloma [10-12]. Though 
there are no reported cases of SPM in untreat-
ed primary amyloidosis except for the limited 
number of cases reported of its delayed pro-
gression to multiple myeloma, it could be 
debated that patients with untreated amyloido-
sis do not survive long enough for other can-
cers to develop [13]. We describe a patient with 
AL amylodosis who was treated with lenalido-
mide and dexamethasone. After 56 months of 
treatment, she developed B-lymphoblastic leu-
kemia. After thorough review of the literature, 
we found no reports of B-cell acute lymphoblas-
tic leukemia occurring after a diagnosis of AL 
amyloidosis. 
Before the advent of immunomodulators there 
have been numerous cases of SPMs in multiple 
myeloma, MGUS and Waldenström’s macro-
globulinemia, but were predominantly of non 
lymphoid origin [13-25]. There are cases 
reports of B-lymphoblastic leukemia in patients 
with multiple myeloma who were treated with 
lenalidomide. However, the increased risk of a 
SPM with lenalidomide was noted when the 
drug was used in combination with alkylating 
agents. The hematologic malignancies found in 
association with multiple myeloma were pre-
dominantly acute myeloid leukemia or myelo-
dysplastic syndromes and a limited number of 
cases of B cell malignancies including acute 
lymphoblastic leukemia, Hodgkin and non-
Hodgkin lymphoma (NHL) [11, 12, 26]. 
In a prospective double blind study by McCarthy 
et al which compared the use of lenalidomide 
versus placebo for maintenance therapy after 
autologous hematopoietic stem-cell transplan-
tation in multiple myeloma, 8 cases of SPMs 
were reported in the lenalidomide group, two of 
which were NHL and ALL [12]. It is unclear as to 
whether these 2 patients had received an alkyl-
ating agent during the treatment course. The 
rest of the malignancies were non-lymphoid in 
origin. A phase 3 placebo-controlled trial for 
multiple myeloma by M. Attal et al, studied 
patients under the age of 65 years with non-
progressive disease who received consolida-
tion treatment with lenalidomide within six 
months of autologous stem-cell transplanta-
tion [11]. At a median follow-up of 34 months 
from randomization and 44 months from diag-
nosis, there were 32 SPMs in 26 patients 
reported in the lenalidomide group versus 12 
SPMs in 11 patients in the placebo group. The 
incidence of SPMs were 3.1 per 100 patient-
years and 1.2 per 100 patient-years for patients 
Figure 2. A: Core bone marrow biopsy showing prominence of plasma cells consistent with AL amyloidosis. B: Bone 
marrow aspirate showing Acute Lymphoblastic Leukemia.
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receiving lenalidomide and placebo (P=0.002), 
respectively. There were 13 reported hemato-
logic cancers with lenalidomide and 5 with pla-
cebo. There were 3 cases of ALL recorded in 
the lenalidomide maintenance arm and none in 
the placebo arm. The MM-015 trial by Palumbo 
et al showed that the 3 year rate of second 
malignancies were 7% each in the two lenalido-
mide treated group versus 3% without lenalido-
mide. There were a total of 25 cases of SPMs 
with no reported incidence of ALL in any of the 
treatment arms [27] (Table 1).
In a retrospective pooled analysis of 11 clinical 
trials of lenalidomide-based therapy of 3846 
patients with relapsed/refractory multiple mye- 
loma, the overall incidence rate (IR, events per 
100 patient years) of SPMs was 3.62 with a 
total of 52 invasive SPMs after a median dura-
tion of lenalidomide based therapy for 5 months 
(range, 0.03-58 months). In a separate analysis 
of pooled data from pivotal phase 3 trials of 
relapsed or refractory MM involving 704 
patients the overall IR of SPMs was 3.98 (95% 
CI 2.51-6.31) with lenalidomide/dexametha-
sone and 1.38 (95% CI, 0.44-4.27) with place-
bo/dexamethasone. In both of these trials 
there were no reports of second hematologic 
malignancies [28]. 
In an earlier issue of this journal, these authors 
reported on an unusual transformation of 2 
cases of MDS 5q- syndrome to acute lympho-
blastic leukemia while on lenalidomide for 32 
and 72 months respectively [29]. Myelody- 
splastic syndromes associated with deletion of 
the long arm of chromosome 5 represent a 
unique entity with an indolent course that is 
less likely to transform into acute leukemia. 
The two patients achieved an initial response 
with lenalidomide however, later on became 
refractory to treatment and evolved into 
B-lymphoblastic leukemia with recurrence of 
the 5q- along with an additional cytogenetic 
abnormality of 20q- in both patients. To our 
knowledge, these are the first two cases report-
ed of MDS evolving into ALL while on lenali- 
domide.
The present case is unique not only because of 
lack of reported cases of acute lymphoblastic 
leukemia after a diagnosis of AL amylodosis, 
but also there was no leukemogenic potentia-
tion with alkylating agents in our patient as 
seen in previous cases of multiple myeloma 
with lenalidomide. This raises questions as to 
whether the development of ALL in this patient 
was a consequence of the IMiDs drugs or 
whether it was a de novo occurrence. Though 
there are increasing reports of SPM with IMiDs 
there has been no convincing clinical data to 
answer these questions. A cytogenetic analysis 
performed in 21 patients with primary amyloi-
dosis showed that the chromosome damage 
identified after melphalan therapy was local-
ized to myeloid but not plasma cells [30]. From 
these data we infer that use of alkylating agents 
could be associated with the incidence of 
myeloid neoplasms in the lenalidomide treat-
ment group. In other distinct studies, transloca-
tions involving the immunoglobulin heavy-chain 
locus (IgH 14q32) have been found as the pos-
sible early genetic events in patients with pri-
mary systemic amyloidosis and multiple myelo-
ma [31-34]. Interestingly similar rearrangements 
involving the immunoglobulin heavy chain locus 
(IgH) at chromosome band 14q32 are reported 
in B-cell precursor acute lymphoblastic leuke-
mia as well [35-43]. To ascertain whether acute 
lymphoblastic leukemia could be the end result 
Table 1. Comparison of the incidence of SPMs in lenalidomide (L) maintenance in recent treatment tri-
als
Trial Follow up months N Number of ALL Total no: of hematologic cancer
Median time to diagnosis of 
hematologic cancer
(CALGB) 100104 [10] 34 L-231 1 8 28 months (range, 12 to 46)
P-229 0 1
IFM 2005-002 study [9] 44 L-306 3 13 -
P-302 0 5
MM-015 [26] 30 MPR-R-150 0 7 -
MPR-152 0 5
MP-153 0 1
Treatment groups: L–lenalidomide, P–Placebo, MPR-R (melphalan, prednisone, and lenalidomide induction followed by maintenance lenalidomide), 
MPR (melphalan, prednisone, and lenalidomide induction), MP (melphalan and prednisone induction).
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of such chromosomal translocations during the 
natural course of light chain (AL) amyloidosis 
and multiple myeloma, and whether IMiDs 
potentiates such genetic changes would require 
longer follow up with meticulous cytogenetic 
analysis.
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